FDA Grants Orphan Drug Status for Anti-Anthrax Drug
Posted on: Tuesday, 7 March 2006, 21:02 CST
By Daily Record Staff & Wire Reports
Medarex Inc., of Princeton, N.J., and PharmAthene Inc., an Annapolis-based biotech that is developing counterterrorism drug products, said the Food and Drug Administration granted them orphan drug status for Valortim, an anti-anthrax drug
. The designation, which is reserved for drugs that treat diseases affecting fewer than 200,000 people, provides a variety of incentives for product development.Source: The Daily Record (Baltimore)
Related Articles
- The Drug Information Center Arthritis Project: Providing Patients With Interactive and Reliable Arthritis Internet Education
- WHO Programme for International Drug Monitoring
- Abnormal Drug Response: Opportunities for Risk Reduction Through Pharmacogenetics
- Advances in Single-Patient Trials for Drug Treatment Optimization and Risk Management*
- 12 Freed for Texas Drug Bust Appeals
- 12 Freed in Appeal of Texas Drug Busts
- 'Rapid Detox' Breaks Drug Habits Quickly
- Advisers: Arthritis Drug Not Too Risky
- 55 Charged With Selling Drug Gear Online
- ADHD Drug Prescriptions Vary by ZIP Code
Rating: 3.4 / 5 (13 votes)
 |
 |
Rate this article:
User Comments (0)
RSS Feeds